# Aaron Davidson

> Aaron Davidson is a Series B investor at H.I.G. BioHealth Partners backing Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [H.I.G. BioHealth Partners](https://shizune.co/investors/profile/h-i-g-biohealth-partners)
- Location: Canmore, Canada
- Total investments: 1
- Last investment: Jul 2006
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/theaarondavidson
- X (Twitter): http://twitter.com/artichikin

Aaron Davidson is a Series B investor at H.I.G. BioHealth Partners in Canmore focused on Health Care and Therapeutics. Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in variousmanagement roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., Cardeas Pharma, HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and Novadaq Technologies. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing.Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alder Biopharmaceuticals | Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Aldertoday will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs. | $16M | Series B | Jul 01, 2006 |  |

1 of 1 investments shown.

## Co-investors
- [Sevin Rosen Funds](https://shizune.co/investors/profile/sevin-rosen-funds) — VC Fund, 1 deal together
- [Ventures West](https://shizune.co/investors/profile/ventures-west) — VC Fund, 1 deal together
- [Washington Research Foundation](https://shizune.co/investors/profile/washington-research-foundation) — VC Fund, 1 deal together
- [WRF Capital](https://shizune.co/investors/profile/wrf-capital-282a) — VC Fund, 1 deal together

## About H.I.G. BioHealth Partners

VC Fund · Miami, United States

H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novelproducts for significant unmet medical needs.

5 contacts available at H.I.G. BioHealth Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Bruce Robertson | Managing Director | https://shizune.co/investors/profile/bruce-robertson |
| Jorge Ramirez | Vice Presidents | https://shizune.co/investors/profile/jorge-ramirez-3 |
| Aaron Davidson | Managing Director | https://shizune.co/investors/profile/aaron-davidson |
| Michael Wasserman | Managing Director | https://shizune.co/investors/profile/michael-wasserman |
| Sami Mnaymneh | Co-Founder | https://shizune.co/investors/profile/sami-mnaymneh |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Aaron Davidson invest in?

Aaron Davidson invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Aaron Davidson last invest?

The most recent investment recorded for Aaron Davidson closed in Jul 2006. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co